Clinical trials: Liver, Cancer of, Non-Resectable
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Liver Cancer
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
- Trial name
- IRE (NCT02333773)
- Testing
- Irreversible electroporation (IRE)
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma.
- Trial name
- NCT06364007
- Testing
- HAIC+STRIDE+Len
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma
Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy
Respiratory-gated, volumetric-modulated arc therapy will be used for the clinical development of high dose rate Stereotactic Body Radiotherapy (SBRT) in inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT01850316
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Carcinoma, Hepatocellular
Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer.
- Trial name
- ALPPS (NCT01722175)
- Testing
- ALPPS surgery, PVO surgery
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine